Shengwu Li

Shengwu Li is a Professor of Economics at Harvard University’s Department of Economics, affiliated with the Faculty of Arts and Sciences (FAS). He previously served as a Junior Fellow of the Society of Fellows. His research spans behavioral economics theory and molecular oncology, focusing on mechanisms of cancer drug resistance, targeted therapies, and epigenetic regulation in tumors. He has contributed to understanding KRAS inhibition resistance, HER2 exon 20 insertion mutations, and synergistic immunotherapies combining epigenetic modifiers with immune checkpoint blockade.

• Education details not explicitly listed in the text.

Research interests include behavioral economic models of decision-making under uncertainty, coupled with experimental studies in cancer biology. His work bridges theoretical economics and translational oncology, addressing challenges in precision medicine and drug development. Recent studies explore therapeutic efficacy of CDK7 inhibitors in pancreatic cancer and mechanisms of adeno-to-squamous transition in lung tumors.

Notable achievements include the Junior Fellow distinction, highlighting early-career excellence in interdisciplinary research. Collaborative projects involve preclinical models of tumor organoids and ex vivo patient-derived spheroids to identify combination therapies for HER2-mutant lung cancers.